BridgeMD
New treatment option for Advanced Breast Cancer
Official title A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
ClinicalTrials.gov ID: NCT06638307
What this study is testing
What is MEN2312?
MEN2312 is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for advanced breast cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participant has advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.
- Presence of genetic alterations in PIK3CA/AKT1/PTEN in participants' tumor tissue.
- Participant must have received at least 1 prior line of endocrine therapy for advanced/metastatic disease or participant who has radiological...
- Progression on previous cyclin-dependent kinase 4 and 6 inhibitor treatment in combination with fulvestrant or aromatase inhibitor is required. Key
You likely can't join if
- Active or newly diagnosed central nervous system metastases.
- Participants with advanced, symptomatic visceral spread, who are at risk of life-threatening complications in the short term, including massive...
- Participants with any toxicities related to prior radiation therapy that have not resolved to baseline or to National Cancer Institute Common...
The study team makes the final eligibility decision.
Where it's taking place
- Springdale, Arkansas, United States
- Duarte, California, United States
- La Jolla, California, United States
- Palo Alto, California, United States
- San Francisco, California, United States
- Santa Monica, California, United States
- New Haven, Connecticut, United States
- Altamonte Springs, Florida, United States
- Orlando, Florida, United States
- Sarasota, Florida, United States
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- Chicago, Illinois, United States
- Iowa City, Iowa, United States
- Fairway, Kansas, United States
- Baltimore, Maryland, United States
- Boston, Massachusetts, United States
- Grand Rapids, Michigan, United States
- Rochester, Minnesota, United States
- East Brunswick, New Jersey, United States
+ 16 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Springdale, Arkansas, United States; Duarte, California, United States; La Jolla, California, United States; Palo Alto, California, United States; San Francisco, California, United States; Santa Monica, California, United States and 30 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.